

J-F Colombel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/704367/j-f-colombel-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

414
papers

40,538
citations

82
h-index

198
g-index

457
ext. papers

50,129
ext. citations

6.9
avg, IF

7.5
L-index

#	Paper	IF	Citations
414	P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i514-i514	1.5	0
413	P655 Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i567-i568	1.5	
412	OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn's Disease: Results from the phase 2 DIVERGENCE 2 study. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i019-i021	1.5	1
411	P117 point-of-care intestinal ultrasound for the detection of postoperative Crohn's disease endoscopic recurrence. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i208-i208	1.5	0
410	P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i452-i452	1.5	
409	DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i088-i089	1.5	2
408	DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn's Disease during treatment with risankizumab. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i125-i126	1.5	0
407	DOP59 Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML). <i>Journal of Crohns and Colitis</i> , 2022 , 16, i105-i106	1.5	
406	P663 Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i572-i573	1.5	
405	P653 The changing epidemiology of IBD in the western world: a population-based study from Denmark. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i566-i567	1.5	1
404	P050 A comparison of the Gut Microbiota in Pregnant Women with and without Inflammatory Bowel Disease and Their Offspring in Hong Kong and United States. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i163-i163	1.5	
403	DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i093-i094	1.5	0
402	DOP16 Categorizing endoscopic severity of Crohn's Disease using the Modified Multiplier SES-CD (MM-SES-CD). <i>Journal of Crohns and Colitis</i> , 2022 , 16, i065-i066	1.5	
401	P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i357-i358	1.5	
400	OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i036-i037	1.5	1
399	Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	1
398	Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.. <i>Gastroenterology</i> , 2022 ,	13.3	3

397	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.. <i>Crohn's & Colitis</i> 360, 2022, 4, otac002	1.4	3
396	Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal-Infant Cohort.. <i>Digestive Diseases and Sciences</i> , 2022, 1	4	0
395	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1592-1601.e3	6.9	22
394	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639	10.4	17
393	A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar. <i>Advances in Therapy</i> , 2021, 1	4.1	
392	Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. <i>BMJ Open</i> , 2021, 11, e049740	3	3
391	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021,	18.8	7
390	P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. <i>American Journal of Gastroenterology</i> , 2021, 116, S8	0.7	0
389	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. <i>United European Gastroenterology Journal</i> , 2021,	5.3	4
388	Luminal Narrowing Alone Allows an Accurate Diagnosis of Crohn's Disease Small Bowel Strictures at Cross-Sectional Imaging. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1009-1018	1.5	1
387	Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 585-589	4.5	20
386	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2207-2209.e3	6.9	10
385	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1443-1454	1.5	5
384	SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1376-1386	1.5	11
383	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1649-1657	1.5	0
382	Aging and IBD: A New Challenge for Clinicians and Researchers. <i>Inflammatory Bowel Diseases</i> , 2021,	4.5	2
381	Reply. <i>Gastroenterology</i> , 2021, 160, 1886-1887	13.3	0
380	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1852-1863	1.5	4

379	The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1877-1884	1.5	10
378	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
377	COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. <i>Gastroenterology</i> , 2021 , 160, 1447-1451	13.3	5
376	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021 , 160, 1570-1583	13.3	191
375	A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1709-1719	0.7	0
374	DOP03 Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S042-S043	1.5	
373	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
372	DOP58 Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S093-S094	1.5	0
371	Diagnostic accuracy of patient-reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. <i>GastroHep</i> , 2021 , 3, 161-168	1	1
370	Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	0
369	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
368	OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S006-S007	1.5	0
367	P065 Conservation of breast milk cytokine profiles in consecutive pregnancies of women with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S170-S171	1.5	
366	P433 Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S435-S436	1.5	1
365	P048 Intestinal inflammation and microbiome diversity are conserved more in consecutive pregnancies among women with inflammatory bowel disease compared to healthy controls. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S156-S158	1.5	
364	P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S305-S305	1.5	
363	P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S350-S351	1.5	78
362	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021 , 160, 2435-2450.e34	13.3	45

361	Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	3
360	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1301-1302	6.9	
359	Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses. <i>EClinicalMedicine</i> , 2021 , 36, 100884	11.3	3
358	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
357	Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. <i>Gastroenterology</i> , 2021 , 161, 47-65	13.3	8
356	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
355	Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 238-245.e4	6.9	6
354	Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. <i>Gastroenterology</i> , 2021 , 160, 287-301.e20	13.3	50
353	Effect of IBD medications on COVID-19 outcomes: results from an international registry. <i>Gut</i> , 2021 , 70, 725-732	19.2	140
352	Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies. <i>Gastroenterology</i> , 2021 , 160, 1118-1130.e3	13.3	12
351	Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 860-863	1.5	6
350	Reply. <i>Gastroenterology</i> , 2021 , 160, 476-477	13.3	
349	The intestinal barrier, an arbitrator turned provocateur in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 83-84	24.2	31
348	Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 394-396.e5	6.9	27
347	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 462-470	1.5	2
346	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 797-808	4.5	4
345	Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study. <i>Gut</i> , 2021 , 70, 1037-1043	19.2	4
344	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 403-405	6.9	8

343	What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries. <i>Inflammatory Intestinal Diseases</i> , 2021 , 6, 78-86	2.5	0
342	The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211004493	4.7	9
341	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4178-4190	4	8
340	Vitamin C Deficiency in Inflammatory Bowel Disease: The Forgotten Micronutrient. <i>Crohns & Colitis</i> 360 , 2021 , 3, otab009	1.4	2
339	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	16
338	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1963-1967	4.5	
337	Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. <i>ACR Open Rheumatology</i> , 2021 , 3, 111-115	3.5	11
336	Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1455-1463	1.5	2
335	Bariatric Surgery and Risk of New-onset Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1474-1480	1.5	3
334	Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
333	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. <i>Gastroenterology</i> , 2021 , 161, 715-718.e4	13.3	55
332	Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021 , 161, 394-399	13.3	6
331	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
330	Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations. <i>Inflammatory Bowel Diseases</i> , 2021 ,	4.5	2
329	Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	2
328	Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. <i>Nature Microbiology</i> , 2021 , 6, 1309-1318	26.6	12
327	Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension. <i>Gastroenterology</i> , 2021 , 161, 1953-1968.e15	13.3	2
326	Validation and Update of the L ² mann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. <i>Gastroenterology</i> , 2021 , 161, 853-864.e13	13.3	5

325	Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. <i>Gastroenterology</i> , 2021 ,	13.3	4
324	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2210-2213.e3	6.9	0
323	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , 2021 , 161, 1156-1167.e3	13.3	2
322	Conjugal inflammatory bowel disease: a systematic review and European survey. <i>Annals of Gastroenterology</i> , 2021 , 34, 361-369	2.2	
321	Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients 2021 ,		1
320	Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 599-632	7.9	2
319	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.. <i>Gut</i> , 2021 ,	19.2	0
318	The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 643-652	4.5	7
317	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 997-998	6.1	1
316	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. <i>Gastroenterology</i> , 2020 , 159, 481-491.e3	13.3	396
315	Systematic review: gastrointestinal infection and incident inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1222-1232	6.1	15
314	Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families. <i>Gastroenterology</i> , 2020 , 159, 381-382	13.3	3
313	Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 73-84	6.1	11
312	What Should Gastroenterologists and Patients Know About COVID-19?. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1409-1411	6.9	43
311	Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. <i>Gastroenterology</i> , 2020 , 159, 96-104	13.3	45
310	Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 831-842	6.1	27
309	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020 , 159, 139-147	13.3	54
308	A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design. <i>Contemporary Clinical Trials Communications</i> , 2020 , 18, 100573	1.8	7

307	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1562-1571	4.5	12
306	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2952-2961.e8	6.9	21
305	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 254-266	1.5	85
304	Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. <i>European Journal of Radiology Open</i> , 2020 , 7, 100217	2.6	4
303	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020 , 158, 2123-2138.e8	13.3	75
302	Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series. <i>Clinical Immunology</i> , 2020 , 212, 108362	9	3
301	P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease: Data from the CALM study. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S264-S266	1.5	
300	Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. <i>Gastroenterology</i> , 2020 , 159, 383-385	13.3	6
299	DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S079-S080	1.5	
298	Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1923-1924	0.7	9
297	JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S755-S760	1.5	16
296	Gastrointestinal involvement attenuates COVID-19 severity and mortality 2020 ,		19
295	Review article: bacteriophages in gastroenterology-from biology to clinical applications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 53-63	6.1	21
294	Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1152-1160.e1	6.9	10
293	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 271-280	6.1	27
292	De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 63-79	18.8	21
291	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 872-880.e1	6.9	9
290	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 553-564	6.1	13

289	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	10
288	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis</i> 360 , 2020 , 2, otaa039	1.4	1
287	P092 Pathogenic B-cell response in ulcerative colitis that associates with treatment resistance and disease complications. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S181-S182	1.5	
286	P457 IBD couples and their offspring: a European survey. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S407-S408	1.5	
285	P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S440-S442	1.5	1
284	P729 The SAPPHERE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HistoRy of CancEr. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S585-S587	1.5	1
283	P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S465-S465	1.5	
282	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 669-681	6.1	21
281	Targeting B cells for inflammatory bowel disease treatment: back to the future. <i>Current Opinion in Pharmacology</i> , 2020 , 55, 90-98	5.1	9
280	P144 Vitamin C deficiency in inflammatory bowel disease: the forgotten micronutrient. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S209-S209	1.5	0
279	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1236-1245	0.7	7
278	P030 Dynamics of intestinal inflammation and microbial dysbiosis in pregnant women with IBD and their infants. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S146-S147	1.5	1
277	Inflammatory Bowel Disease Therapy and Venous Thromboembolism. <i>Current Treatment Options in Gastroenterology</i> , 2020 , 18, 462-475	2.5	1
276	Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	6
275	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1353-1365	6.1	34
274	IBD in the COVID-19 era: the value of international collaboration. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 887-888	18.8	8
273	Defined microbiota transplant restores Th17/ROR γ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21536-21545	11.5	22
272	Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity. <i>Gut</i> , 2020 , 69, 401-402	19.2	6

271	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 23-32	1.5	75
270	Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. <i>Gut</i> , 2020 , 69, 42-51	19.2	67
269	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1518-1527.e3	6.9	15
268	Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2020 , 158, 95-110	13.3	47
267	Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 257-258	6.9	6
266	Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 267-273	1.5	6
265	DOP15 Transmural healing with vedolizumab in patients with active Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S053-S056	1.5	
264	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. <i>Cell Host and Microbe</i> , 2020 , 27, 823-829.e3	23.4	42
263	Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1621	6.1	
262	P413 A simple scoring tool predicts exposure-response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S316-S316	1.5	
261	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 1007-1018.e7	13.3	82
260	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. <i>International Journal of Colorectal Disease</i> , 2019 , 34, 1771-1779	3	8
259	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1215-1226	59.2	240
258	Neonatal Life Events and the Risk of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019 , 157, 1440-1441.e3	1.3	0
257	Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1525-1532.e1	6.9	71
256	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S018-S020	1.5	6
255	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S024-S025	1.5	12
254	DOP35 Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn's disease, is significantly amplified in patients with a complicated phenotype. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S045-S046	1.5	

253	Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 564-571	6.1	7
252	Systematic review with meta-analysis: association between <i>Helicobacter pylori</i> CagA seropositivity and odds of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 121-131	6.1	19
251	Challenges in IBD Research: Preclinical Human IBD Mechanisms. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, S5-S12	4.5	26
250	Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019 , 29, 421-436	3.3	28
249	Association Between <i>Helicobacter pylori</i> Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2185-2198.e3	6.9	26
248	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1854-1861	4.5	9
247	Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics. <i>Contemporary Clinical Trials Communications</i> , 2019 , 14, 100345	1.8	9
246	Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1257-1264	1.5	6
245	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1148-1157	1.5	7
244	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019 , 156, 1333-1344.e3	13.3	36
243	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 473-479	2.4	98
242	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 287-295	18.8	29
241	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 796-797	6.9	
240	P314 Long-term fate of the excluded rectum in Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S257-S258	1.5	
239	P404 Stopping 5-aminosalicylates in Crohn's disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S310-S311	1.5	
238	P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S312-S313	1.5	
237	P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S274-S275	1.5	7
236	P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S433-S433	1.5	

235	Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. <i>Gut</i> , 2019 , 68, 2152-2160	19.2	19
234	The Role of Early Biologic Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1896-1905	4.5	40
233	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 573-574	6.9	
232	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1227-1233	15.3	5
231	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 163-171	4.5	5
230	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 130-138.e7	6.9	44
229	Diffusion and perfusion MRI quantification in ileal Crohn's disease. <i>European Radiology</i> , 2019 , 29, 993-1002		16
228	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2019 , 114, 874-883	0.7	90
227	Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies. <i>Journal of Autoimmunity</i> , 2019 , 105, 102303	15.5	14
226	Gut microbiota density influences host physiology and is shaped by host and microbial factors. <i>ELife</i> , 2019 , 8,	8.9	72
225	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1189-1194	6.1	12
224	Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 57-63	3.3	1
223	Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM). <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	13
222	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S612-S613	1.5	19
221	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2019 , 156, 1440-1454.e2	13.3	169
220	P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the Phase 3b VERSIFY trial. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S293-S294	1.5	1
219	Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 904-911	6.1	20
218	Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 725-734	1.5	19

217	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2497-2505.e1	6.9	25
216	P360 Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S284-S285	1.5	0
215	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 50-57	1.5	39
214	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1533-1540.e2	6.9	40
213	Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. <i>Gut</i> , 2019 , 68, 977-984	19.2	27
212	Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and ROR γ Regulatory T Cells and Exacerbate Colitis in Mice. <i>Immunity</i> , 2019 , 50, 212-224.e4	32.3	189
211	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 411-418.e3	6.9	23
210	Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 316-323	4.3	20
209	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 380-390.e1	6.9	58
208	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1673-1679.e1	6.9	13
207	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. <i>Gut</i> , 2019 , 68, 615-622	19.2	17
206	Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1126-1134	6.1	13
205	OP009 A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn's disease: results from a population-based study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, S007-S007	1.5	1
204	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1374-1384	6.9	59
203	Identification of volumetric laser endomicroscopy features of colon polyps with histologic correlation. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 1558-1564	5.2	2
202	Urbanization and the gut microbiota in health and inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 440-452	24.2	114
201	Clinical disease activity in the CALM study - Authors' reply. <i>Lancet, The</i> , 2018 , 391, 1482	4.0	1
200	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. <i>Gastroenterology</i> , 2018 , 154, 1201-1202	13.3	17

199	Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 896-905	6.1	74
198	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 892-899.e2	6.9	45
197	Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. <i>Gastroenterology</i> , 2018 , 154, 1037-1046.e2	13.3	167
196	Efficient long-term depletion of CD20 B cells by rituximab does not affect gut-resident plasma cells. <i>Annals of the New York Academy of Sciences</i> , 2018 , 1415, 5-10	6.5	9
195	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 610-620	1.5	37
194	Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 718-729	1.5	34
193	Systematic review: safety of mesalazine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1597-1609	6.1	49
192	High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1106-1113.e3	6.9	45
191	Agreement Between Crohn's Disease Endoscopic Severity Scores Derived from Live, Video-recorded, and Central Readings. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, e6-e7	4.5	
190	Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 446-447	6.1	2
189	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 76-87	13.3	29
188	Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. <i>Human Pathology</i> , 2018 , 79, 42-49	3.7	12
187	Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 538-545	1.5	57
186	The Management of Intestinal Penetrating Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 752-765	4.5	20
185	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018 , 67, 244-254	19.2	73
184	Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 234-243.e2	6.9	47
183	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2018 , 154, 61-64.e6	13.3	46
182	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 687-695.e10	13.3	60

181	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 785	6.9	2
180	A characterization of pro-inflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model. <i>International Immunopharmacology</i> , 2018 , 60, 194-201	5.8	26
179	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 1558-1570	9.2	46
178	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1053-1066	15.6	13
177	Adherent-invasive in inflammatory bowel disease. <i>Gut</i> , 2018 , 67, 574-587	19.2	204
176	The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2018 , 6, 112-122	5.3	51
175	Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 219-228	6.1	27
174	A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN'S DISEASE. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 153-154	0.5	78
173	Uric acid levels are independent of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease: A reappraisal of the role of S. cerevisiae in this setting. <i>Virulence</i> , 2018 , 9, 1224-1229	4.7	6
172	The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 1101-1108	4.2	22
171	Anti- $\alpha\beta$ 7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	42
170	Microbial-Host Interactions in Inflammatory Bowel Disease, Functional Bowel Disease, Obesity and Obesity-Related Metabolic Disease. <i>Gastroenterology</i> , 2018 , 155, 1283-1286	13.3	1
169	P160 Faecal Lactoferrin is a reliable IBD biomarker during pregnancy. <i>Journal of Crohns and Colitis</i> , 2018 , 12, S178-S178	1.5	3
168	Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. <i>Gastroenterology</i> , 2018 , 155, 1079-1089.e3	13.3	93
167	A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB IN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN'S STUDIES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 219-220	0.5	2
166	Diet Modifies Colonic Microbiota and CD4 T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23. <i>Gastroenterology</i> , 2018 , 155, 1177-1191.e16	13.3	22
165	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 1045-1058	13.3	85
164	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2461-2467	4.5	33

163	Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2173-2182	4.5	61
162	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 65-77	6.1	80
161	Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. <i>The Cochrane Library</i> , 2018 , 5, CD012540	5.2	16
160	Clinical updates on perianal fistulas in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 597-605	4.2	8
159	A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE-SEVERE CROHN'S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 147-148	0.5	1
158	Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1345	0.7	87
157	De-escalation of Therapy in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2018 , 20, 35	5	10
156	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , 2017 , 66, 588-596	19.2	82
155	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 801-813	6.1	64
154	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017 , 66, 839-851	19.2	478
153	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017 , 66, 1049-1059	19.2	203
152	Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. <i>Gut</i> , 2017 , 66, 2063-2068	19.2	72
151	Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1315	6.9	3
150	Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1200-1204	1.5	25
149	Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1481-1492	6.1	33
148	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 142-149	6.1	79
147	Crohn's disease. <i>Lancet, The</i> , 2017 , 389, 1741-1755	40	829
146	Ulcerative colitis. <i>Lancet, The</i> , 2017 , 389, 1756-1770	40	1146

145	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 921-929	1.5	99
144	Eldelumab [anti-interferon-Inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 811-819	1.5	19
143	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 441-448.e2	4.5	72
142	Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. <i>Gastroenterology</i> , 2017 , 152, 309-312	13.3	48
141	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 533-541	6.1	26
140	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2779-2789	40	403
139	Peroxisome proliferator-activated receptor gamma (PPAR) regulates lactase expression and activity in the gut. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1471-1481	12	15
138	P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey. <i>Journal of Crohns and Colitis</i> , 2017 , 11, S456-S457	1.5	
137	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 281-288	1.5	14
136	Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 425-434	1.5	15
135	Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1702-1709	4.5	121
134	Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1908-1914.e2	6.9	6
133	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 264-275	6.1	27
132	Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1571-1579	4	33
131	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017 , 152, 351-361.e5	13.3	153
130	Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk. <i>International Journal of Colorectal Disease</i> , 2017 , 32, 453-458	3	7
129	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 50-62	6.1	42
128	P121 Antimicrobial antibodies and inflammatory markers are present in the serum of patients with IBD years before diagnosis and can predict disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, S136-S137	1.5	

127	OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301). <i>Journal of Crohns and Colitis</i> , 2017 , 11, S11-S12	1.5	2
126	Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade [®]] or Conventional Therapy. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 680-689	1.5	41
125	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 412-424	1.5	112
124	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 400-411	1.5	109
123	Genetics and phenotypes in inflammatory bowel disease. <i>Lancet, The</i> , 2016 , 387, 98-100	4.0	29
122	Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. <i>Mucosal Immunology</i> , 2016 , 9, 767-76	9.2	37
121	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. <i>Mucosal Immunology</i> , 2016 , 9, 322-35	9.2	31
120	Features of Patients With Crohn's Disease and Hidradenitis' Suppurativa. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 71-9	6.9	26
119	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2016 , 375, 2102	59.2	41
118	Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn's Disease. <i>MBio</i> , 2016 , 7,	7.8	218
117	Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature. <i>Digestive and Liver Disease</i> , 2016 , 48, 893-8	3.3	10
116	Mortality and Rates of Graft Rejection or Failure Following Intestinal Transplantation in Patients With vs Without Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1574-1581	6.9	6
115	Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1753-1762	6.9	13
114	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 1946-1960	59.2	896
113	Polymorphisms in the Mannose-Binding Lectin Gene are Associated with Defective Mannose-Binding Lectin Functional Activity in Crohn's Disease Patients. <i>Scientific Reports</i> , 2016 , 6, 29636	4.9	8
112	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1147-55	0.7	198
111	Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1416-1423	0.7	35
110	Reply. <i>Gastroenterology</i> , 2016 , 150, 1039	13.3	

109	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1385-1394	1.5	74
108	Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. <i>Gut</i> , 2016 , 65, 954-62	19.2	76
107	P-016 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S14	4.5	
106	Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 695-702	1.5	12
105	Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. <i>American Journal of Gastroenterology</i> , 2016 , 111, 477-91	0.7	106
104	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1245-1255.e8	6.9	158
103	Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e148	4.2	24
102	Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e135	4.2	285
101	Agreement of site and central readings of ileocolonoscopy scores in Crohn's disease: comparison using data from the EXTEND trial. <i>Gastrointestinal Endoscopy</i> , 2016 , 83, 188-97.e1-3	5.2	18
100	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 418-28	1.5	38
99	Increased Risk of Oral Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 413-20	6.9	16
98	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 58-64	6.9	65
97	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016 , 150, 389-95.e3	13.3	30
96	Chemotherapy tolerance and oncologic outcomes in colorectal cancer (CRC) patients with and without inflammatory bowel disease (IBD).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15162-e15162	2.2	
95	P-017 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S14	4.5	
94	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 252-61	6.1	77
93	The features of mucosa-associated microbiota in primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 790-801	6.1	85
92	Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 317-33	6.1	180

91	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. <i>Gut</i> , 2016 , 65, 1061-9	19.2	42
90	Response to Cote-Daigneaut et al. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1851-1852	0.7	
89	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016 , 151, 97-109.e4	13.3	83
88	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-to-Severe Crohn's Disease Refractory to Anti-TNF. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S1	4.5	39
87	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 483	6.9	
86	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1361-2	6.9	
85	Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 966-972.e2	6.9	23
84	Anti-TNF Withdrawal in Inflammatory Bowel Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2016 , 23, 153-161	1.1	5
83	B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 3407-3424	4	20
82	Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1806-1815	0.7	48
81	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, e121-2	6.9	2
80	Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1347-8	6.1	
79	Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1300-10	6.1	62
78	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2233-40.e1-2; quiz e177-8	6.9	92
77	Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 1043-52	1.5	22
76	Inflammatory bowel disease and the elderly: a review. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 507-15	1.5	82
75	Intestinal steroidogenesis controls PPAR α expression in the colon and is impaired during ulcerative colitis. <i>Gut</i> , 2015 , 64, 901-10	19.2	31
74	Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 734-46	6.1	111

73	Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 781-95	4.2	36
72	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015 , 149, 1716-30	13.3	141
71	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1324-38	0.7	1024
70	Mycobiota in gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 77-87	4.2	105
69	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. <i>Gastroenterology</i> , 2015 , 148, 37-51.e1	13.3	162
68	Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. <i>Gut</i> , 2015 , 64, 438-46	19.2	56
67	Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1082-92	6.1	51
66	Review article: non-malignant oral manifestations in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 40-60	6.1	34
65	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. <i>PLoS ONE</i> , 2015 , 10, e0120299	3.7	36
64	High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 266-75	1.5	31
63	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34	27.4	102
62	Biologics in inflammatory bowel disease: what are the data?. <i>United European Gastroenterology Journal</i> , 2015 , 3, 419-28	5.3	79
61	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015 , 47, 356-64	3.3	29
60	Management of severe ulcerative colitis. <i>Current Treatment Options in Gastroenterology</i> , 2015 , 13, 59-76	2.5	2
59	Factors associated with short- and long-term outcomes of therapy for Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 539-547.e2	6.9	60
58	Identifying strains that contribute to complex diseases through the study of microbial inheritance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 633-40	11.5	48
57	Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2015 , 4, e23	2	40
56	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 443-68	1.5	633

55	Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , 2014 , 146, 96-109.e1	13.3	482
54	IBD across the age spectrum: is it the same disease?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 88-98	24.2	139
53	Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1771-80 ^{0.7}	10.7	103
52	IBD therapy: new targets and unmet needs. <i>Nestle Nutrition Institute Workshop Series</i> , 2014 , 79, 153-60	1.9	2
51	Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1728-38	0.7	202
50	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014 , 63, 1416-23	19.2	94
49	Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1083-4	0.7	3
48	Decade in review-IBD: IBD-genes, bacteria and new therapeutic strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 652-4	24.2	11
47	Systematic review: Monotherapy with antitumour necrosis factor agents versus combination therapy with an immunosuppressive for IBD. <i>Gut</i> , 2014 , 63, 1843-53	19.2	86
46	Adalimumab induces deep remission in patients with Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 414-22.e5	6.9	174
45	Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. <i>Gastroenterology</i> , 2014 , 146, 941-9	13.3	138
44	Improving quality of care in inflammatory bowel disease: what changes can be made today?. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 919-26	1.5	55
43	Reply: To PMID 23644079. <i>Gastroenterology</i> , 2014 , 146, 868-9	13.3	
42	DOP037 Long-term outcome of paediatric-onset ulcerative colitis: early years are shaping the future. <i>Journal of Crohns and Colitis</i> , 2014 , 8, S32-S33	1.5	2
41	Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 423-31.e1	6.9	100
40	Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 469-79	1.5	101
39	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. <i>Gastroenterology</i> , 2014 , 147, 618-627.e3	13.3	468
38	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , 2014 , 146, 85-95; quiz e14-5	13.3	572

37	Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PATients in Crohn's diseasE Questionnaire (SPACE-Q()). <i>Patient Preference and Adherence</i> , 2014 , 8, 1671-81	2.4	2
36	Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 950-7	1.5	73
35	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , 2013 , 369, 711-21	59.2	1328
34	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2	1465
33	Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. <i>Gastroenterology</i> , 2013 , 145, 978-986.e5	13.3	124
32	Geographical variability and environmental risk factors in inflammatory bowel disease. <i>Gut</i> , 2013 , 62, 630-49	19.2	365
31	Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 213-21	1.5	113
30	Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1236-47	6.1	79
29	PPAR-gamma in ulcerative colitis: a novel target for intervention. <i>Current Drug Targets</i> , 2013 , 14, 1501-73		43
28	Therapeutic drug monitoring of biologics for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 349-58	4.5	96
27	Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , 2012 , 142, 257-65.e1-3	13.3	842
26	Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. <i>Gastroenterology</i> , 2012 , 142, 1102-1111.e2	13.3	402
25	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 991-1030	1.5	715
24	105 Natural History of Ulcerative Colitis in the Elderly: A Population-Based Study. <i>Gastroenterology</i> , 2012 , 142, S-25	13.3	2
23	Ulcerative colitis as a progressive disease: the forgotten evidence. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1356-63	4.5	133
22	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. <i>Gut</i> , 2012 , 61, 241-7	19.2	216
21	A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1051-63	0.7	153
20	Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. <i>Gastroenterology</i> , 2011 , 141, 1621-28.e1-5	13.3	337

19	Baseline C-reactive protein is associated with disease progression in patients with Crohn's disease P-34.. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S22	4.5	
18	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 306-17	6.1	33
17	Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1296-309	6.1	78
16	Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1574-82	0.7	165
15	The natural history of pediatric ulcerative colitis: a population-based cohort study. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2080-8	0.7	227
14	Adalimumab safety in global clinical trials of patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1308-19	4.5	98
13	Risk factors for opportunistic infections in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2008 , 134, 929-36	13.3	756
12	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. <i>Gastroenterology</i> , 2007 , 132, 52-65	13.3	1668
11	Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 146, 829-38	8	704
10	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. <i>Gut</i> , 2006 , 55, 749-53	19.2	1831
9	Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005 , 19 Suppl A, 5A-36A		2167
8	Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. <i>Gut</i> , 2005 , 54, 357-63	19.2	156
7	High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. <i>Gastroenterology</i> , 2004 , 127, 412-21	13.3	1104
6	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 505-12	5.2	948
5	Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. <i>Gut</i> , 2003 , 52, 552-7	19.2	203
4	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. <i>Nature</i> , 2001 , 411, 599-603	50.4	4469
3	Inflammatory bowel disease microbiotas alter gut CD4 T-cell homeostasis and drive colitis in mice		1
2	Gut microbiota density influences host physiology and is shaped by host and microbial factors		1

- 1 Defined microbiota transplant restores Th17/ROR γ + regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas

3